Rosetta and Moffitt Partner to Develop microRNA Cancer Diagnostic
|
By LabMedica International staff writers Posted on 16 Jun 2014 |
|
Rosetta Genomics, Ltd. (Princeton, NJ, USA; Rehovot, Israel), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, has entered into an agreement with Moffitt Cancer Center (Tampa, FL, USA) to advance the development and commercialization of Rosetta's thyroid neoplasia assay. Rosetta will work with Marino Leon, MD, associate member of the department of anatomic pathology at Moffitt.
Kenneth A. Berlin, president and CEO of Rosetta Genomics commented, “Results from our initial studies demonstrated that microRNA expression levels can differentiate malignant nodules from benign nodules, and also demonstrated our ability to extract and profile microRNAs from thyroid fine-needle aspirations [FNAs] in various sample types and in a way consistent with common clinical practices. This agreement with Moffitt will help us further advance the development of this important assay, and should allow us to achieve our goal of launching this important assay prior to the end of 2015.”
Dr. Marino Leon noted, “Many patients with indeterminate thyroid FNA results are sent to surgery as a precaution, despite the fact that the majority of these cases are benign. This exposes patients to unnecessary surgical risk and costs the system hundreds of millions of dollars.”
Rosetta Genomics cancer tests are a series of microRNA-based diagnostic testing services. The Rosetta Cancer Origin test can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). The company’s assays are offered directly by Rosetta Genomics in the United States, and through distributors around the world. Rosetta’s cancer testing services are commercially available through its Philadelphia (PA, USA)-based College of American Pathologists (CAP)-accredited, Clinical Laboratory Improvement Amendments (CLIA)-certified lab.
Rosetta’s research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools and therapeutics.
Moffitt is one of only 41 US National Cancer Institute-designated comprehensive cancer centers, a distinction that recognizes Moffitt's excellence in research, its contributions to clinical trials, prevention and cancer control. Moffitt is the No. 1 cancer hospital in Florida and has been listed in US News & World Report as one of “America's Best Hospitals” for cancer since 1999.
Related Links:
Rosetta Genomics
Moffitt Cancer Center
Kenneth A. Berlin, president and CEO of Rosetta Genomics commented, “Results from our initial studies demonstrated that microRNA expression levels can differentiate malignant nodules from benign nodules, and also demonstrated our ability to extract and profile microRNAs from thyroid fine-needle aspirations [FNAs] in various sample types and in a way consistent with common clinical practices. This agreement with Moffitt will help us further advance the development of this important assay, and should allow us to achieve our goal of launching this important assay prior to the end of 2015.”
Dr. Marino Leon noted, “Many patients with indeterminate thyroid FNA results are sent to surgery as a precaution, despite the fact that the majority of these cases are benign. This exposes patients to unnecessary surgical risk and costs the system hundreds of millions of dollars.”
Rosetta Genomics cancer tests are a series of microRNA-based diagnostic testing services. The Rosetta Cancer Origin test can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). The company’s assays are offered directly by Rosetta Genomics in the United States, and through distributors around the world. Rosetta’s cancer testing services are commercially available through its Philadelphia (PA, USA)-based College of American Pathologists (CAP)-accredited, Clinical Laboratory Improvement Amendments (CLIA)-certified lab.
Rosetta’s research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools and therapeutics.
Moffitt is one of only 41 US National Cancer Institute-designated comprehensive cancer centers, a distinction that recognizes Moffitt's excellence in research, its contributions to clinical trials, prevention and cancer control. Moffitt is the No. 1 cancer hospital in Florida and has been listed in US News & World Report as one of “America's Best Hospitals” for cancer since 1999.
Related Links:
Rosetta Genomics
Moffitt Cancer Center
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Portable POCT Blood Gas Analyzer
BD100
Automatic CLIA Analyzer
Shine i6000
Latest Industry News
- New NHS Partnership Expands Access to Epigenetic CNS Tumor Classifiers
- Fujirebio Expands Access to Automated Blood-Based Neurology Testing in Canada
- Natera ctDNA Test to Support Response Monitoring in Solid Tumor Trial
- Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring
- Companion Diagnostics Expand HER2 Testing in Metastatic Gastroesophageal Cancer
- Global Urinalysis Market Gowth Driven by Demand for Automated and POC Testing
- New Collaboration Expands Point-of-Care Testing Across UK Community Pharmacies
- New Collaboration Advances Precision Oncology Screening for Lung Cancer in Japan
- AI-Powered Pathology Collaboration Supports Companion Diagnostic Development
- Strategic Collaboration Expands Commercial Access to Oncology Companion Diagnostics
- Collaboration Supports Global ADC Development with AI-Powered Tissue Analysis
- Standardized Staining Technology Advances Digital Pathology Workflows
- Global Testing Service Advances Leukemia MRD Monitoring
- Ultrasensitive MRD Assay Gains Medicare Coverage for Immunotherapy and Breast Cancer Monitoring
- Genprex and Roche Collaborate on AI-Driven NSCLC Biomarker Testing
- Collaboration Explores Clinical Use of Single-Cell and Spatial Technologies
Channels
Clinical Chemistry
view channel
New Blood Biomarker Predicts May Predict Preeclampsia and Fetal Growth Restriction
Preeclampsia and fetal growth restriction are major drivers of stillbirth and serious maternal morbidity, yet clinicians still lack reliable early predictors to guide targeted surveillance.... Read more
Biomarker Score Helps Differentiate Takotsubo Syndrome from Myocardial Infarction
Takotsubo syndrome, often called broken-heart syndrome, mimics myocardial infarction and can be difficult to triage in emergency settings. It accounts for about 2% of suspected heart attacks and up to... Read more
Molecular Diagnostics
view channel
Automated System Streamlines DNA Recovery for MRD-Sensitive Testing
Molecular laboratories are under pressure to detect extremely low levels of residual disease, yet pre-analytical recovery of cell-free and genomic DNA from large-volume blood and plasma remains a persistent... Read more
New Liquid Biopsy Platform Uses Red Blood Cells to Detect Hidden Cancer Signals
Plasma-based liquid biopsy can miss clinically actionable tumor signals, particularly in early-stage disease and low-shedding tumors, limiting its utility for routine monitoring. Clinical laboratories... Read more
Hematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read more
Immunology
view channel
New Cellular Map May Help Predict Crohn’s Disease Course in Children
Crohn’s disease in children is a common and debilitating form of inflammatory bowel disease, marked by chronic intestinal inflammation and limited pediatric-specific treatments. Clinicians must decide... Read more
Temporal Immune Profiling Reveals How Sepsis States Change Over Time
Sepsis is a life-threatening condition in which the immune response to infection becomes dysregulated, leading to rapid organ failure and death. Although antimicrobials and organ support remain standard... Read more
Study Identifies Immune Cells That Drive Harmful Autoantibody Responses in COVID-19
Autoantibodies that mistakenly attack the body’s own tissues have been linked to severe COVID-19, Long COVID, and increased risk of autoimmune disease. However, the origins of these autoantibodies during... Read more
Microbiology
view channel
Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification
Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours
Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more
Pathology
view channel
Label-Free Imaging Reveals Hidden Immune Activity in Blood Samples
Peripheral blood mononuclear cells (PBMCs) are widely used to monitor infection, autoimmunity, cancer, and treatment response, yet most assays depend on fluorescent labels that can perturb cells and provide... Read more
AI Tool Improves Prediction of Immunotherapy Response in Lung Cancer
Immune checkpoint therapies benefit only a subset of patients, while standard biomarkers often struggle to predict who will respond. Spatially resolved tumor profiling can provide deeper biological context,... Read more
Technology
view channel
Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read more
